Antios Therapeutics

, (Antios) is a biopharmaceutical company that develops novel therapies to treat and cure Hepatitis B Virus (HBV) and other viral diseases. The company’s product is a novel ASPIN (Active Site Polymerase Inhibitor Nucleotide) called ATI-2173 that targets the liver and is a potentially curative therapy for chronic Hepatitis B Virus. The company designed this drug to deliver 5’- monophosphate of clevudine to the liver where it is metabolized to the active 5’-triphosphate. This provides a potential HBV antiviral activity, improved pharmacokinetic profile for clinical use, reduced systemic exposure of clevudine, no toxic results to cells, the potential elimination of skeletal myopathy and off-treatment suppression of HBV DNA. ATI-2173, a descendant of clevudine, to be administered orally once daily, is a nucleotide that restrains all stages of DNA synthesis. Unlike traditional NA’s (Nucleoside Analogues) that inhibit viral replication one genome at a time, the company’s drug prohibits replication one polymerase at a time. Antios conducts research and development for chronic HBV infection. Current therapies including chain-terminating NA, result in viral replication in over 90% of patients upon discontinuing the treatment.

1. Series B

   Nov 3, 2021

   Amount

   $75M

   Investors

   Locked

2. Series B

   Apr 9, 2021

   Amount

   $32M

   Investors

   Locked

3. Series A

   Oct 31, 2018

   Amount

   $15M

   Investors

   Locked